In one of the largest, multicentre studies to date, the use of anti-IL6 treatments was associated with increased of IFD in the COVID-19 cohort (OR: 2.93, P: 0.0017), and the dual use of dexamethasone and anti-IL6 treatments were significantly associated with CAPA (OR: 2.7, P:0.027) (51). This evidence concerns the gene IL6 and episodic ataxia type 2.